

Hysterectomy in Morbidly Obese Women: A Retrospective Comparative Analysis of Routes Vaginal Versus Abdominal in Benha University Hospital

Ashraf Nassif, Aziza A. Negmb, Yehia M. Edris

Department of Obstetrics and Gynecology, Faculty of Medicine Benha University, Egypt.

Corresponding to: Yehia M. Edris Department of Obstetrics and Gynecology, Faculty of Medicine Benha University, Egypt.

Email:

yehiaedris77@gmail.com

Received: 22 August 2023

Accepted: 23 November 2023

Abstract

Objective: To compare perioperative surgical, medical, and financial outcomes in morbidly obese women who underwent non-descent vaginal hysterectomy (NDVH) compared to total abdominal hysterectomy (TAH) for non-prolapse indications.

Patients and methods: A retrospective analysis included 117 women who underwent hysterectomies performed between January 2015 and March 2023 in Benha University Hospital. The NDVH group included 55 women. The TAH group included 62 women. **Results:** Both NDVH and TAH groups participants had statistically indifferent pre-operative mean hemoglobin levels, age, parity, associated comorbidities, previous pelvic and abdominal surgery involving cesarean sections, and comparable indications for hysterectomy ($p > 0.05$), but statistically higher BMI, HBA1c preoperative serum level, and shorter preoperative hospital admission (days), all these items favoring the superiority NDVH group over the TAH group ($p = 0.0001$). There were no statistical differences between groups as regards operative room time, operative blood loss, intra-operative complications, removed uterine weight in grams, and the need

for blood transfusion ($p > 0.05$). While there were high statistical differences ($p < 0.0001$) favoring outcomes of NDVH over TAH including the need for general anesthesia, wound complications percentage (1% vs 72%), shorter postoperative hospital stays, less consumption of analgesic and shorter duration needs for postoperative venous thromboembolic prophylaxis, earlier ambulation, earlier to pass flatus. Approximate charges of both procedures were encouraging the NDVH over TAH ($p < 0.0001$). **Conclusion:** In morbidly obese women with non-prolapsed uteri, the NDVH should be the primary route for hysterectomy, as the NDVH results is better than the TAH results in all perioperative outcomes items.

Keywords: non-descent vaginal hysterectomy; vaginal hysterectomy; morbidly obese; total abdominal hysterectomy; retrospective study

Introduction:

Morbid obesity defined as Body Mass Index (BMI) $\geq 40\text{kg/m}^2$ is an increasing healthcare problem in the USA as well as worldwide (1,2,3). Centers for Disease Control and Prevention reported that the actual number may be underrated (3). Present estimations propose that 48.9% of the US population will be obese by 2030 and one in four adults will be severely obese (7.7% in 2013-2014 to 24.2% by 2030) (4,5). In Canada, recent guidelines of the Society of Obstetrics and Gynecology of Canada (SOGC) regarding hysterectomy in obese women reported that one in five women are obese (6), while the magnitude of the obesity problem is indeterminate in Egypt, despite that there was a declaration at a political level to be a significant economic problem.

Simultaneous with the rise in worldwide obesity rates, the number of women who underwent hysterectomy rises, reported in the USA to be 600 000 annually (1,7,8). The rate of hysterectomies in Egypt is unknown, however, it is generally higher than expected, secondary to messy unregulated health policies. In Egypt, many surgical specialties could operate hysterectomies even in governmental health institutes, not merely obstetric and gynecologic generalists rather than expert vaginal gynecologists.

In the United States, 66% of hysterectomies are executed abdominally, and 22% are executed vaginally (7), while in Egypt there is underutilization of the vaginal route and nearly gynecologic surgeon in charge deliberated morbid obesity as a contraindication for vaginal hysterectomies and only a few gynecologists nationwide who practiced non-descent vaginal hysterectomy as a trial based routine gynecologic practice (10-13).

The vaginal route for hysterectomy is excellent to other procedures of hysterectomy in terms of patient's safety, security, economics, cosmesis, perioperative morbidity and supported over other routes by policy statements from the American College of Obstetricians and Gynecologists (ACOG), the American Association of Gynecologic Laparoscopists (AAGL), SOGC and International Society for Gynecologic Endoscopy (ISGE)(6,8,14-16) as well as the medical literature (17-22).

Non-Descent Vaginal Hysterectomy (NDVH) in the morbidly obese woman is complexed by redundant vaginal tissue especially in parous obese patients rather than nulliparous obese patients, prominent buttocks, and lack of descent. To overcome such problems in morbidly obese women undergoing NDVH, gynecologic surgeon should be patient, confident, knowing how to implement available multiple techniques for peritoneal access, has the accessibility to execute the NDVH procedures with aids of new tools for vessel sealing, vaginal surgery visualization instruments and patients should be in a position for optimal visualization, (17-27).

Morbid obesity is falsely perceived as a contraindication to NDVH. TVH was the procedure of choice by Heaney and Bonney in generalas well as in obese women. Some gynecologists go so far as to say there is no absolute contraindication to vaginal hysterectomy includes large sizes and positional limits, The FIGO prior president states that once gynecologic surgeon could visualize cervix vaginally, he should trial hysterectomy vaginally (17-27).

Morbidly obese women are associated with an elevated risk of death and general morbid conditions (1-8).

A specific adverse effect after gynecologic surgery, such as surgical site infection, venous thromboembolism, and wound complications, are more frequent in obese women than in normal-weight women (8,9,28-43). Preoperative consultation with an anesthesiologist should be considered for obese patient in whom the possibility of obstructive sleep apnea is suspected on clinical grounds or who is at risk of coronary artery disease, has a difficult airway, or has poorly controlled hypertension (1,6,7,8). Gynecologic surgeons should know how to support obese women on the threats specific to this group (6,7). As with all patients, evidence demonstrates that, in general, vaginal hysterectomy is associated with better outcomes and fewer complications than laparoscopic or abdominal hysterectomy (9,28-43). Postoperative care of the obese patient is like postoperative care of a normal-weight patient and comorbid conditions should be taken into consideration (28-43). In obese women, the incidence of wound complications including poor healing, dehiscence either partial or total, and infections after open surgery were significantly increased (35- 43). Wound complications have been one of the major anxieties in obese women who undergo abdominal hysterectomy as well (30-35,39). Because vaginal hysterectomy by default abolishes the need for abdominal wounds, and sequentially wound complications, entirely, it is intuitive to suggest that the vaginal approach may be more favorable for obese women (17-27).

Our intentions were to measure perioperative outcomes of TAH and NDVH in morbidly obese women in Benha University hospitals, to add evidence to what is already known in

literature about the superiority of the vaginal route for hysterectomy and to convince Egyptian gynecologic surgeon to follow recommendations by gynecological societies, namely ACOG, AAGL, SOGC, SGS, RCOG and ISGE.

Patients and Methods:

A retrospective analysis included 117 women who underwent hysterectomies performed between January 2015 and March 2023 in Benha University Hospital. The NDVH group included 55 women. The TAH group included 62 women.

This is a retrospective study in which, all available of charts morbid obese women with $BMI \geq 40 \text{ kg/m}^2$ who underwent either TAH or NDVH between January 2015 and March 2023 at the Obstetrics and Gynecology Department of Benha University Hospital, Benha, Egypt were examined and relevant data were extracted and tabulated. Ethical approval was granted from the Benha Faculty of Medicine ethical committee (NO: 39.5.2023). Written consent from participants was unneeded according to the default nature of the retrospective study. All NDVH cases were operated by the first author, while TAH cases were operated by experienced gynecologists. Women were included if their BMI was $\geq 40 \text{ kg/m}^2$, underwent hysterectomy for benign uterine diseases, the procedure was performed either vaginally or abdominally, anesthetized either generally or spinally, older than 18 years and their clinical follow-up data until completely cured or ≥ 30 days postoperatively were available as well as their uteri weren't prolapsed \geq second-degree uterine descent even under anesthesia. We excluded women if they

had one of the following criteria :(1) women with suspected malignancy, (2) women found to be second-degree uterine decent or more after execution of the anesthesia, (3) women in whom a major surgical intervention other than hysterectomy was performed, (4) cases with incomplete medical records or who failed to be followed for 30 days postoperatively. Pre-operative collected parameters included age, BMI, comorbid conditions such as diabetes mellitus, hypertensive disorders, liver diseases, renal disorders, orthopedics problems, airway obstructive disorders, indications for hysterectomy, parity, hemoglobin concentration (CBC), previous abdominal or vaginal surgery and length of preoperative hospital entrance (LOPA) to control the comorbid status as uncontrolled diabetes mellitus (LOPA) as well as percentage of glycated hemoglobin A1C (HBA1C).

Intra-operative collected data were the type of surgical methods either conventional suturing or vessel sealing-based procedures as well as additional actions such as bilateral oophorectomy BS, bilateral salpingo-oophorectomy BSO, cystectomy, added techniques like morcellation as in NDVH, operative time, type of anesthesia either general or spinal, estimated blood loss (EBL), Intra-operative complications included major blood vessel or organ injury (including bowel, bladder, and ureter) and need for blood transfusion.

Post-operative collected data were length of inpatient stay (LOS), hemoglobin concentration (CBC), hospital readmission; return to theatre; vault or pelvic vault hematoma, vault dehiscence, vault abscess, vault cellulitis, abdominal wound status in the TAH group including seroma collection, cellulitis, wound dehiscence, need to reoperate on wound sequels,

length of wound care, pelvic infection, urinary tract infection, thromboembolic disease prophylaxis needs and duration of consumption as well as other medical status deterioration. The collected data of all included women in this analysis were summarized and anonymized.

We categorized total expenses, according to nearby private centers prices in deeming expenses estimation at time of writing this manuscript, into three divides: admission expense, anesthesia charge, and operation cost. Admission expenses included ward fee, pre-and postoperative administration expenses, and extra fees for postsurgical troubles. Anesthesia cost only involved prices of anesthetic drugs during procedure. Operation charge included operative material prices but omitted elective practice fees as private fees and governmental salaries.

Outcome measures were: 1) Operative time (OT), 2) EBL, 3) Decline in hemoglobin (Δ HB) value (the alteration between preoperative and postoperative, 4) Operative complications as blood transfusion, conversion in case of NDVH or relaparotomy in TAH, bowel or visceral injuries, 5) Early postoperative follow up including (a) postoperative pain either no pain, mild pain, moderate pain, severe pain, and very severe pain, (b) length of hospital stay (LOS), (c) Febrile morbidity (body temperatures $> 38^{\circ}\text{C}$ in two consecutive measurements > 4 hours apart), (d) requisite for analgesia, (e) time to pass stool or gas from end of the procedures, (f) time to get out of bed activity (hours), 7) remote postoperative follow up includes recuperation time and postoperative vaginal length, 8) approximate total expenses of both procedures.

Statistical analysis was executed by Medcalc easy-to-use statistical software for Windows desktop (www.medcalc.org)

2016. Continuous variables were given as mean \pm 2 standard deviations and range, independent samples student's t-test was used to compare continuous variables. Categorical variables were given as numbers and percentages and were assisted using either Fisher's exact test or Pearson's Chi-square test as analysis methods to identify differences between the NDVH and TAH groups. Statistical significance was deemed if p was <0.05 .

Results:

In this retrospective analysis, 55 women were undergoing NDVH while 62 women underwent TAH between January 2015 and March 2023 in Benha University hospitals.

In table (1) the clinical and demographic characteristics of morbidly obese women were exhibited. Women in both groups were parallel about age, parity, clinical uterine extent (weeks), ultrasound uterine volume (Cm^3), nonexistent prior vaginal birth, postoperative uterine weightiness (grams), preoperative hemoglobin (gm/dl), the linked preoperative medical comorbidities as well as the cause for hysterectomy. Table (1) also shows significant difference regarding the BMI (kg/m^2) ($p < 0.0001$), higher percent of women with uncontrolled diabetes mellitus (DM) ($p < 0.0001$) in the NDVH group, briefer LOPA to control the medical comorbidities ($p < 0.0001$) in the NDVH group and higher HBA1C% ($p < 0.0001$) in the NDVH group. All these parameters supported the preeminence of NDVH over the TAH, as women with greater BMI and with higher preoperative HBA1C (an indicator for uncontrolled diabetes mellitus) were operated vaginally and also admitted for briefer preoperative period as there were no expected abdominal wound so no requirement to wait for lowering HBA1C which takes very longer preoperative admission in TAH group.

Table (2) shows no significant differences between groups regarding total OT, EBL, intraoperative complications including visceral injuries, blood transfusion, conversion to laparotomy. In the NDVH group there was one case due to inability to access the vesico-uterine pouch secondary to large solitary uterine leiomyoma. There were significant differences between groups regarding the percent of women who underwent conventional suturing were more in the TAH group ($p < 0.0006$) while women who underwent vessel sealing were more in the NDVH group. This could be attributed to the adoption of the concept of energy-based surgery earlier in TVH and this is well known in gynecological practice.

As regards type of anesthesia, there was more general anesthesia in the TAH group ($p < 0.0001$) while most NDVH were significantly competed under initial spinal anesthesia ($p = 0.0001$). In all cases of the NDVH group morcellations techniques were applied while in the TAH group, such procedures were very infrequent ($p < 0.0001$). In the NDVH group more women significantly underwent BS ($p < 0.0001$), while in the TAH group, significantly excess women underwent BSO ($p < 0.0001$), all these differences could be attributed to differences in mindsets of vaginally motivated gynecologist whom always challenging themselves. Incidentally, the percent of women with postoperative uterine weight less than 100 grams was more in the NDVH group ($p = 0.03$). This could be explained on basis of electing for definitive treatment by NDVH operator once the patient choice it. Approximate expenses of admission, anesthetic drugs, operative materials were significantly lesser in the NDVH group ($p < 0.0001$).

The early and late postoperative outcomes data in this retrospective analysis were displayed in table 3. The percent of women in the NDVH group that showed a

severe pain status at 6h and 24 h postoperative was significantly lesser ($p < 0.0001$) while the consumption of analgesia both narcotic and NSAID was significantly lower ($p = 0.0002$ and $p < 0.0001$ respectively) in the NDVH group. The decline in 24-hour hemoglobin was not significant between both groups ($p = 0.6$). Also, no significant differences between groups regarding febrile morbidity, vaginal spotting, pelvic cellulitis, and cystitis ($p > 0.5$). While there

were significant differences between NDVH and TAH groups regarding the time to move out of bed ($p < 0.0001$), time to outflow flatus ($p < 0.0001$), LOS ($p < 0.0001$), resuming usual activity time ($p < 0.0001$), wound complications ($p < 0.0001$), reoperation for the wound ($p = 0.003$), requirement for venous thromboembolism (VTE) prophylaxis ($p < 0.0001$) and time of VTE prophylaxis ($p < 0.0001$) which were superior in the NDVH group.

Table (1): Demographic and clinical characteristics of morbidly obese women with BMI ≥ 40 kg/m² underwent NDVH and TAH.

Variable	NDVH (no =55)	TAH (no = 62)	Δ (95% CI)	P value
- Age (year)	49.6 \pm 5.2 (41 – 62)	49.8 \pm 4.8 (40 – 65)	0.2 (-1.63 to 2.03)	0.8
- Parity	2.4 \pm 1.5 (0 - 5)	2.5 \pm 1.6(0 – 6)	0.1 (-0.47 to 0.67)	0.7
- BMI (kg/m ²)	51.6 \pm 4.6 (41.5 – 60.5)	46.3 \pm 5.8 (40.5 – 58.6)	-5.3 (-7.23 to -3.36)	0.0001
- Clinical uterine size (weeks)	11.3 \pm 3.1 (6 – 20)	11.6 \pm 2.8 (6 – 20)	0.3 (-0.78 to 1.38)	0.5
- Ultrasound uterine volume Cm ³	145 \pm 66 (55 – 700)	155 \pm 87 (60 – 900)	10 (-18,56 to 38.56)	0.4
-Absent of previous vaginal birth	10(18%)	12(19%)	1% (-13.4% to 14.9%)	0.8
-preoperative HB (g/dl)	12.1 \pm 1.1(10.5-13.5)	11.9 \pm 0.9(10.8-12.9)	-2 (-0.56 to 0.16)	0.2
- Previous pelvic surgery:				
- Cesarean section	18 (32%)	22(35%)	3% (-13.9% to 19.4%)	0.7
- other	8 (14%)	12(19%)	5% (-8.9% to 18.3%)	0.4
-virgin lower abdomen	31(56%)	32(51%)	5% (-12.7% to 22.2%)	0.6
- Comorbidity:				
- HTN	46(83%)	54(87%)	4% (-9.1% to 17.5%)	0.5
- DM	49(89%)	52(83%)	6% (-7.1% to 18.6%)	0.3
- uncontrolled DM	45(81%)	49(79%)	2% (-12.7% to 16.2%)	0.7
-PHBA1C (%)	14.1 \pm 3.5(5.1%-18.4%)	10.3 \pm 4.6(4.9%-17.8%)	-3.69 (-5.2 to 2.1)	0.0001
-LOPA (days)	3.5 \pm 1.5(2-7)	30.5 \pm 10.5(20-40)	27 (24.1 to 29.8)	0.0001
- Indication for hysterectomy:				
- PMB	45(81%)	52(83%)	2% (-11.88% to 16.28%)	0.7
- EH	35(63%)	39(62%)	1% (-16.22% to 17.95%)	0.9
-CIN	5(9%)	8(12%)	3% (-9.03% to 14.56%)	0.6
- Adenomyosis	6(10%)	9(14%)	4% (-8.54% to 16.06%)	0.5
- Fibroid	8 (14%)	13(20%)	6% (-8.06% to 19.43%)	0.3

NDVH: Non-Descent Vaginal Hysterectomy; **TAH:** Total Abdominal Hysterectomy; **BMI:** Body Mass Index; **HTN:** Hypertension; **DM:** Diabetes Mellitus; **PMB:** Perimenopausal Bleeding; **EH:** Endometrial Hyperplasia; **CIN:** Cervical Intraepithelial Neoplasia; **PHBA1C:** Pre-Operative Glycated Hemoglobin A1C; **LOPA:** Length of Preoperative Admittance; $p < 0.05$: statistically significant, Values were given as mean \pm 2 standard deviation (range) or number (percent).

Table (2): Comparison of intra-operative outcome measures and expenses between morbidly obese women with BMI $\geq 40\text{kg/m}^2$ who underwent NDVH and TAH.

Outcome	NDVH (no = 55)	TAH (no = 62)	Δ (95% CI)	pvalue
Total operative time (min)	120 \pm 40 (90 – 180)	110 \pm 45 (80-150)	-10(-25.6to5.5)	0.2
Conventional surgical procedures	18(33%)	40(65%)	32%(13.8%to47.2%)	0.0006
Vessel-sealing surgical procedures	37(67%)	22(35%)	32%(13.8%to47.2%)	0.0006
Operative blood loss (ml)	525 \pm 170(300-750)	550 \pm 180(350 -950)	25(-39.3to89.3)	0.4
General anesthesia	5(9%)	50(80%)	71%(55.4%to80.5%)	0.0001
Spinal anesthesia	50(90%)	12(19%)	71% (55.4%to80.5%)	0.0001
Additional techniques	55(100%)	5(8%)	92%(80.5%to96.5%)	0.0001
Intraoperative complications*				
- visceral injuries	2 (vesical) (3%)	3 (vesical) (4%)	1%(-6.5%to9.5%)	0.7
- blood transfusion	4(7%)	5(8%)	1%(-9.8%to11.3%)	0.8
-conversion to laparotomy	2(3%)	n.a		
Concomitant procedures				
-BS	31(57%)	10(16%)	40%(22.7%to54.2%)	0.0001
- BSO	24(43%)	52(84%)	40%(22.7%to54.2%)	0.0001
- others	6(10%)	5(8%)	2%(-8.9%to13.6%)	0.7
Approximate expenses*				
admission expense	2.18 \pm 0.345(1.1-3.7K)	5.145 \pm 0.55(2-8K)	2.96 (2.78 to 3.13)	<0.0001
anesthesia expense	0.42 \pm 0.085(.19-.9K)	2.43 \pm 0.97(1.5-3.9K)	2.01 (1.74 to 2.27)	<0.0001
operation expense	5.15 \pm 0.768(4-5.5 K**)	8.685 \pm 1.75(7-9K)	3.52 (3.02 to 4.03)	<0.0001
- P. O uterine weight(gram)	190 \pm 85 (60 – 1050)	180 \pm 85 (65 – 950)	-10 (-41.18 to 21.18)	0.5
-Uterus weight (category)				
-Small (≤ 100 g)	4(7.2%)	0(0%)	7.2% (0.09%to17.1%)	0.03
-Standard (101–300 g)	32(58%)	43(65%)	7% (-10.3% to 23.9%)	0.43
-Large (301–600 g)	14(25.4%)	13(20.9%)	4.5% (10.6%to19.7%)	0.56
-Very large (>600 g)	5(9%)	6(9%)	0% (-11.5% to 10.9%)	1

NDVH: Non-Descent Vaginal Hysterectomy; **TAH:** Total Abdominal Hysterectomy; **Δ (95% CI):** Point estimate difference with 95% confidence interval; **BS:** Bilateral salpingectomy; **BSO:** Bilateral Salpingo-Oophorectomy; **P.O:** postoperative, *: approximate costs were determined in Egyptian currency (LE), **: K=1000LE; Values were given as mean \pm standard deviation(range) or number (percent); **P<0.05:** Statistically significances

Table (3): Comparison of early and late postoperative outcome measures between morbidly obese women with BMI $\geq 40\text{kg/m}^2$ who underwent NDVH and TAH.

Outcome	NDVH (no = 55)	TAH (no = 62)	Δ (95% CI)	P value
Postoperative pain				
- severe at 6h	25(45%)	55(88%)	43%(26.3 to56.7)	0.0001
- severe at 24 h	5(9%)	45(72%)	63%(46.9 to 73.9)	0.0001
Analgesic requirements over 24h				
-Total narcotic (mg)	19.8 \pm 8.2(10-40)	38.2 \pm 9.8(20-60)	18(15.1 to 21.73)	0.0001
-Total parental NSAID (mg)	150.5 \pm 55.5(100-300)	240.5 \pm 120.6(200-500)	90(54.8 to 125.1)	0.0001
Time to get out of bed (h)	5.6 \pm 1.7(2-12)	8.8 \pm 5.6(6-24)	3.2(1.6to4.7)	0.0001
Time to flatus(h)	7.2 \pm 3.2(3-24)	18.1 \pm 9.2(10-50)	10.9(8.3 to 13.4)	0.0001
decline in hemoglobin at (24h)	1.8 \pm 1.1(.8-1.7)	1.7 \pm 1.3(.9-1.9)	-0.1(-0.5 to 0.3)	0.6
LOS (days)	1.5 \pm 0.5(1-10)	18.5 \pm 8.9(7-70)	17(14.6 to 19.3)	0.0001
Return to usual activity time (day)	9.6 \pm 4.6(3-15)	35.3 \pm 11.9(15-90)	25(22.3 to 29.1)	0.0001
Febrile morbidity	28 (9.5%)	35 (14.2%)	4.7%(-7.7% to 16.7%)	0.4
Vaginal spotting	48 (87%)	5(8%)	79%(64.2%to86.9%)	0.0001
Pelvic cellulitis	5 (9%)	3(4%)	5%(-4.5%to15.8%)	0.2
Cystitis	8 (14%)	4(6%)	8%(-3.1%to20.1%)	0.1
Wound complications	1(1%)	45(72%)	71%(56.7%to80.6%)	0.0001
Reoperation for wound	1(1%)	15(24%)	23%(11.4%to34.9%)	0.0003
Need for VTE prophylaxis(days)	20(36%)	62(100%)	64%(49.5%to75.3%)	0.0001
Duration of VTE prophylaxis(days)	1.9 \pm 1.1 (1-7)	8.5 \pm 3.4 (5-15)	6.6(5.7to7.5)	0.0001

NDVH: Non-descent Vaginal Hysterectomy; **TAH:** Total Abdominal Hysterectomy, **Δ (95% CI):** Point estimate difference with 95% confidence interval, **NSAID:** Non-steroidal anti-inflammatory drugs, **VTE:** venous thromboembolism, **LOS:** length of postoperative stay in hospital; $p < 0.05$: statistically significant, Values were given as mean \pm 2 standard deviation (range) or number (percent).

Discussion:

This retrospective study concentrated on morbidly obese women with type III obesity with BMI $\geq 40\text{kg/m}^2$ who undergoing major gynecological surgery, specifically TAH and NDVH as such sector of women were understudied both retrospectively as well as prospectively as stated in systematic review on a hysterectomy in morbidly obese (36). Despite, the high expectations for morbid obesity in the United States, Canada, and the rest of the world, including Egypt, in the nearest future (1-6), as well as the high expectations for hysterectomy needs (7–10), we believed that our paper as an Egyptian analysis of NDVH on morbid obese women was a unique research piece that addressed this incredibly difficult problem.

Impact of obesity was investigated on TAH by comparing nonobese versus obese in 1976 and author reported that wound complications were seven times more in obese (29). Also, impact of obesity was investigated on vaginal hysterectomy (VH) by comparing nonobese versus obese in 1977 and author stated that, obesity does not appear to inflict added risks in vaginal hysterectomy, in conflict to abdominal hysterectomy in which the raised morbidity relays to wound infection (30). Studies after 1976 rarely compare TAH to VH in obese, despite the availability of studies comparing TAH to total laparoscopic and robotic hysterectomy (TLH) (6,17 14,32,36,37). Moreover, our prior prospective studies didn't address this sector of women (10-13). A recent retrospective analysis in 2017 investigate VH in morbidly obese comparing conventional suturing technique to vessel sealing technology reported very low conversion rate as well as very low complication rate (23), but it only compared

vaginal to vaginal and conducted on morbidly obese women with average BMI.

A Cochrane review on surgical approaches to hysterectomy for benign gynecologic diseases states that the vaginal approach must be considered the best choice for uterus removal because of its association with fewer complications, reduced operating time, decreased hospitalization, lower costs, and shorter convalescence compared with AH (9). Despite the demonstrated advantages of VH as a type of natural orifice surgery (17-23), VH accounts for only 23% of hysterectomies performed in the United States (7,8,9,38). The route of hysterectomy is commonly selected fitting to the experience and capability of the surgeon where the vaginal route was discovered to be unsuitable to most of gynecologic surgeon even in the USA (40) and UK (41). So, TVH is seeming omission to evidence-based decision-making. Morbidly obese women had projecting buttocks, redundant vaginal tissue, decreased soft tissue pliability and this was claimed to be challenges to execute NDVH (17-22,40,41). So, several strategies were recommended to facilitate NDVH in morbidly obese women including extended lithotomy position, energy-based vessel sealing (EBVS), different morcellations techniques including cervical amputation after anterior and posterior colpotomies, uterine bisection, myomectomy and uterine coring (24,25,26) as well as gynecologist motivation, patience, training, and experience.

The outcomes of this analysis favoring NDVH over TAH were in parallel with the results of many research articles (27, 28,29,30,32,31,33,34,38,39,40,42), as regards outcomes of TAH and VH in obese women and morbidly obese including intraoperative and postoperative outcomes

measures. In France, a study evaluates impact of obesity on MIH including TVH, TLH, RH, they found that the least performed is TVH (8%) and class 3 obesity associated with highest expenses (43). A Canadian survey reported 4% in their cohort underwent hysterectomy were class 3 obesity and reported that both TAH, TLH, TVH could safely performed in obese when compared to non-obese (44).

An American survey evaluated complications corresponding to BMI in 55,409 hysterectomies for benign indications in the National Surgical Quality Improvement Project in the USA, reported that in TAH, women with BMIs of ≥ 40 had an odd ratio (OR) around five for wound dehiscence or wound infection and an OR of 1.9 for sepsis and also reported the magnitude of the connotation between wound infection and BMI was slighter after TVH and the recommended that in obese women TVH or TLH should be executed whenever feasible (38).

A prospective comparison of obesity impact on TVH and LAVH for the non-prolapsed uterus reported that both procedures were feasible and safe alternate for obese patients showing comparable perioperative outcome measures as non-obese patients undergoing TVH and LAVH and the authors stated that, TVH should be preferred to LAVH as it is a safe route of hysterectomy, with procedure time being significantly quicker (62.8 ± 9.3 vs. 29.9 ± 6.6 min in non-obese women, and 62.7 ± 9.8 vs 30.0 ± 6.9 min for obese women) (45).

Moreover, this study is the first article showing that women in the NDVH group had significantly higher BMI and PHBA1C while shorter LOPA (Table 1). This could be explained based on referring morbid obese patients to NDVH gynecologist. Also, this study shows that significant shift

toward utilizing EBVS during NDVH, lower need to convert to general anesthesia, higher utilizations of morcellations in the NDVH group as well as more addressing the removal of tubes and ovaries on NDVH group (Table 2), and lower consumption of prophylaxis for VTE (Table3). All these items were secondary to changing the concept towards NDVH and dealing with all hysterectomy as a trialed vaginal by the principal investigator. Such an attitude towards NDVH was recommended by Pioneer of gynecologic surgery (gynecologic surgeons) (17-27,40,41).

This study's strengths were its retrospective nature being low cost and assessing actual status of surgical performances, relatively larger sample size to other studies as well as comparing NDVH to TAH in women with BMI ≥ 40 kg/m², addressing surgical outcomes specifically in morbidly obese patients who underwent NDVH, challenging an actual well-known contraindication to TVH as morbid obesity, nulliparity, lack of uterine mobility, prior lower abdominal surgery, and bulky uterine size.

This study's limitations were being a retrospective analysis includes selection biases, reporting biases, confounders such surgical experience of the gynecologists as well as an inability to generalize the outcomes as it is single institute results and the skills of NDVH were limited and underutilized all over the world.

CONCLUSIONS:

The keynote outcome of our study is that the NDVH rather than TAH should be the preferred procedure specifically for morbidly obese utilizing the vessel sealing rather than conventional suture and adapting the concept of trial vaginal hysterectomy in all cases with benign uterine conditions.

Acknowledgments: We would wish to thank Benha university hospital's senior gynecologists for allowing us to utilize data from their patients with BMI ≥ 40 kg/m² who underwent TAH.

References:

1. Matsuo K, Mandelbaum RS, Nusbaum DJ, Matsuzaki S, Klar M, Roman LD., et al. National trends and outcomes of morbidly obese women who underwent inpatient hysterectomy for benign gynecological disease in the USA. *Acta Obstetrica et Gynecologica Scandinavica*. 2021 Mar;100(3):459-70.
2. Prevalence of Obesity Among Adults and Youth: United States, 2015–2016. National Center for Health Statistics. Centers for Disease Control and Prevention. <https://www.cdc.gov/nchs/products/databriefs/db288.htm>.
3. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet*. 2016 Apr 2;387(10026):1377-1396. doi: 10.1016/S0140-6736(16)30054-X. Erratum in: *Lancet*. 2016 May 14;387(10032):1998.
4. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. *NCHS Data Brief*. 2020 Feb;(360):1-8. PMID: 32487284.
5. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C., et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *N Engl J Med*. 2019 Dec 19;381(25):2440-2450. doi: 10.1056/NEJMsa1909301. PMID: 31851800.
6. Yong PJ, Thurston J, Singh SS, Allaire C. Guideline No. 386-Gynaecologic Surgery for Patients with Obesity. *Journal of Obstetrics and Gynaecology Canada*. 2019 Sep 1;41(9):1356-70.
7. Wright, J. D., Herzog, T. J., Tsui, J., Ananth, C. V., Lewin, S. N., Lu, Y. Set et al., Nationwide trends in the performance of inpatient hysterectomy in the United States. *Obstetrics and gynecology*, (2013). 122(2 0 1), 233.
8. American College of Obstetricians and Gynecologists. Committee opinion no. 619. Gynecologic surgery in the obese woman. *Obstet Gynecol*. 2015;125:274–8
9. Nieboer TE, Johnson N, Lethaby A, Tavender E, Curr E, Garry R, et al. Surgical approach to hysterectomy for benign gynecological disease. *The Cochrane Database of Systematic Reviews* 2015, Issue 12. Art. No.: CD003677.
10. Elmantwe, A., Ibrahim, A. Role of interleukin -6 (IL-6) in evaluating surgical stress after total abdominal hysterectomy (TAH) and non—descent vaginal hysterectomy (NDVH). *The Egyptian Journal of Fertility of Sterility*, 2016; 20(2): 12-19. doi: 10.21608/egyfs.2016.19529
11. Elmantwe, A. Bipolar Endometrial Resection (BER) Versus Non-Descent Vaginal Hysterectomy (NDVH) For Leiomyoma Induced Heavy Menstrual Bleeding. *The Egyptian Journal of Fertility of Sterility*, 2017; 21(1): 9-16. doi: 10.21608/egyfs.2017.19223.
12. Assar, T., Elmentawy, A., Mosaad, A., Abdelazim, E. Role of Incisional infiltration with intraperitoneal instillation analgesia in non-descent vaginal hysterectomy. *Evidence-Based Women's Health Journal*, 2017; 7(4): 155-162. doi: 10.21608/ebwhj.2018.5583
13. Nassif, A., Elnory, M. Impact of prophylactic bilateral salpingectomy on ovarian reserve in women undergoing vaginal hysterectomy: A randomized controlled trial. *Evidence-Based Women's Health Journal*, 2020; 10(2): 150-161. doi: 10.21608/ebwhj.2020.22949.1074
14. Matteson KA, Butts SF. ACOG Committee opinion No 701: choosing the route of hysterectomy for benign disease. *OBSTETRICS AND GYNECOLOGY*. 2017 Jun 1;129(6):E155-9.
15. AAGL Advancing Minimally Invasive Gynecology Worldwide. AAGL Position Statement: Route of hysterectomy to treat

- benign uterine disease. *J Minim Invasive Gynecol.* 2011;18:1–3.
16. Chrysostomou A, Djokovic D, Edridge W, van Herendael BJ. Evidence-based practical guidelines of the International Society for Gynecologic Endoscopy (ISGE) for vaginal hysterectomy. *European Journal of Obstetrics & Gynecology and Reproductive Biology.* 2020 Sep 1;252:118-26.
 17. Sheth SS. Vaginal hysterectomy as a primary route for morbidly obese women. *Acta Obstet Gynecol Scand.* 2010;89:971–974.
 18. Sheth SS. *Vaginal Hysterectomy.* 2nd ed. Jaypee Brothers (UK) Medical Publishers LTD. ; 2014.
 19. Tamussino K. .Vaginal Hysterectomy in the Obese Patient. In: Alkatout, I., Mettler, L. (eds) *Hysterectomy.* Springer, Cham. [https://doi.org/10.1007/978-3-319-22497.\(2018\).-8_128](https://doi.org/10.1007/978-3-319-22497.(2018).-8_128)
 20. Keller JM, Gaba ND. Vaginal hysterectomy. *Gynecologic Care.* 2018 Feb 15:89.
 21. Muffly TM, Kow NS. Effect of obesity on patients undergoing vaginal hysterectomy. *J Minim Invasive Gynecol.* 2014; 21(2): 168–175, doi: 10.1016/j.jmig.2013.07.017.
 22. Pandey D, Hebbar S, Inukollu PR, Lobo VV, Bansal S, Solipuram D., et al. An audit of hysterectomy in a teaching hospital in India: Story of a decade. *Journal of the Chinese Medical Association.* 2023 May 1;86(5):506-14.
 23. Karacan T, Ozyurek E, Wetherilt LS, Kiyak H, Yilmaz S, Kaya E. Safety and efficacy of using advanced electro-surgical bipolar vessel sealing during vaginal hysterectomy in morbidly obese patients: a retrospective cohort analysis. *Ginekologia Polska.* 2017;88(10):523-9.
 24. Schmitt JJ, Carranza Leon DA, Occhino JA, Weaver AL, Dowdy SC, Bakkum-Gamez JN ., et al. Determining Optimal Route of Hysterectomy for Benign Indications: Clinical Decision Tree Algorithm. *Obstet Gynecol.* 2017 Jan;129(1):130-138. doi: 10.1097/AOG.0000000000001756.
 25. Paparella P, Sizzi O, Rossetti A, De Benedittis F, Paparella R. Vaginal hysterectomy in generally considered contraindications to vaginal surgery. *Arch Gynecol Obstet.* 2004 Sep;270(2):104-9. doi: 10.1007/s00404-003-0505-x.
 26. Sirota I, Tomita SA, Dabney L, Weinberg A, Chuang L. Overcoming barriers to vaginal hysterectomy: An analysis of perioperative outcomes. *J Turk Ger Gynecol Assoc.* 2019 Feb 26;20(1):8-14. doi: 10.4274/jtgga.galenos.2018.2018.0021.
 27. McMahon MD, Scott DM, Saks E, Tower A, Raker CA, Matteson KA. Impact of obesity on outcomes of hysterectomy. *J Minim Invasive Gynecol.* 2014 Mar-Apr;21(2):259-65. doi: 10.1016/j.jmig.2013.08.707.
 28. Isik-Akbay EF, Harmanli OH, Panganamamula UR, Akbay M, Gaughan J, Chatwani AJ. Hysterectomy in obese women: a comparison of abdominal and vaginal routes. *Obstet Gynecol.* 2004;104:710–714.
 29. Pitkin RM. Abdominal hysterectomy in obese women. *Surg Gynecol Obstet.* 1976; 142(4):532-36.
 30. Pitkin RM. Vaginal hysterectomy in obese women. *Obstetrics and Gynecology.* 1977 May 1;49(5):567-9.
 31. Rasmussen KL, Neumann G, Ljungstrom B, Hansen V, Lauszus FF. The influence of body mass index on the prevalence of complications after vaginal and abdominal hysterectomy. *Acta Obstet Gynecol Scand* 2004;83(1):85–8.
 32. Shah DK, Vitonis AF, Missmer SA. Association of body mass index and morbidity after abdominal, vaginal, and laparoscopic hysterectomy. *Obstet Gynecol* 2015; 125(3):589–98.
 33. Bogani, G., Cromi, A., Serati, M., Di Naro, E., Casarin, J., Pinelli, C et al., Laparoscopic and vaginal approaches to hysterectomy in the obese. *European Journal of Obstetrics & Gynecology and Reproductive Biology,* (2015). 189, 85-90.
 34. Harmanli OH, Dandolu V, Isik EF, Panganamamula UR, Lidicker J. Dose obesity affect the vaginal hysterectomy outcomes? *Arch Gynecol Obstet.* 2011 Apr;283(4):795-8. doi: 10.1007/s00404-010-

- 1422-4. Epub 2010 Mar 17. PMID: 20237934.
35. Osler M, Daugbjerg S, Frederiksen BL, Ottesen B. Body mass and risk of complications after hysterectomy on benign indications. *Hum Reprod* 2011;26(6): 1512–8.
36. Blikkendaal MD, Schepers EM, van Zwet EW, Twijnstra AR, Jansen FW. Hysterectomy in very obese and morbidly obese patients: a systematic review with cumulative analysis of comparative studies. *Arch Gynecol Obstet*. 2015;292:723–738.
37. Mikhail E, Miladinovic B, Velanovich V, Finan MA, Hart S, Imudia AN. Association between obesity and the trends of routes of hysterectomy performed for benign indications. *Obstet Gynecol*. 2015;125:912–918.
38. Shah DK, Van Voorhis BJ, Vitonis AF, Missmer SA. Association between body mass index, uterine size, and operative morbidity in women undergoing minimally invasive hysterectomy. *J Minim Invasive Gynecol*. 2016; 23:1113–1122.
39. Khavanin, N., Lovecchio, F. C., Hanwright, P. J., Brill, E., Milad, M., Bilimoria, K. et al., The influence of BMI on perioperative morbidity following abdominal hysterectomy. *American journal of obstetrics and gynecology*, (2013). 208(6), 449-e1. *Obstet Gynaecol Can*. 2022 Sep;44(9):953-959. doi: 10.1016/j.jogc.2022.04.018. Epub 2022 May 20. PMID: 35598864; PMCID: PMC9481667.
40. Rafii, A., Samain, E., Levardon, M., Darai, E., & Deval, B. Vaginal hysterectomy for benign disorders in obese women: a prospective study. *BJOG: An International Journal of Obstetrics & Gynaecology*, (2005). 112(2), 223-227.
41. Miskry T, Magos A. A national survey of senior trainees surgical experience in hysterectomy and attitudes to the place of vaginal hysterectomy. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2004 Aug;111(8):877-9.
42. Mitas L, Rogulski L, Ziebinski J. Does obesity complicate perioperative course in patients undergoing abdominal hysterectomy. *Archives of gynecology and obstetrics*. 2012 Aug; 286:385-8.
43. Le Neveu M, AlAshqar A, Kohn J, Tambovtseva A, Wang K, Borahay M. Impact of Obesity on Clinical and Financial Outcomes of Minimally Invasive Hysterectomy for Benign Conditions. *J*
44. Cybulsky M, Murji A, Sunderji Z, Shapiro J, Elliott C, Shirreff L. Assessing the impact of obesity on surgical quality outcomes among patients undergoing hysterectomy for benign, non-urgent indications. *Eur J Obstet Gynecol Reprod Biol*. 2022 Jul;274:243-250. doi: 10.1016/j.ejogrb.2022.05.024. Epub 2022 May 23. PMID: 35688107.
45. Locher JA, Chrysostomou M, Djokovic D, Libhaber E, van Herendael BJ, Chrysostomou A. The impact of obesity on vaginal hysterectomy and laparoscopically-assisted vaginal hysterectomy outcomes: A randomised control trial. *Eur J Obstet Gynecol Reprod Biol*. 2023 Aug;287:227-231. doi: 10.1016/j.ejogrb.2023.06.001. Epub 2023 Jun 5. PMID: 37390

To cite this article: Ashraf Nassif, Aziza A. Negm, Yehia M. Edris. Hysterectomy in Morbidly Obese Women: A Retrospective Comparative Analysis of Routes Vaginal Versus Abdominal in Benha University Hospital. *BMFJ* 2024;41(4):76-88.

